Company intelligence / Profile preview

Emyria Limited

Ownership: Private
Development stage: Preclinical

Overview

EMD-RX5 is in Phase 3 clinical trials for over-the-counter registrations. EMD-RX7 is preparing for Phase 1 trials, with preclinical studies showing 4x bioavailability compared to Epidyolex™.

Therapeutic areas: PsychiatryNeurology
Modalities: Cannabinoid-based medicinesMDMA-inspired compounds
Industry: Biotech

Drug pipeline

1 asset

EMD-RX5

Partnerships

Cann GroupProf Matt Piggott (University of Western Australia)

Beyond the preview

Go deeper on Emyria Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emyria Limited.